Direct Biologics v. Kimera Labs, Inc.

CourtDistrict Court, E.D. Missouri
DecidedMarch 30, 2024
Docket4:18-cv-02039
StatusUnknown

This text of Direct Biologics v. Kimera Labs, Inc. (Direct Biologics v. Kimera Labs, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Missouri primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Direct Biologics v. Kimera Labs, Inc., (E.D. Mo. 2024).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION

DIRECT BIOLOGICS, LLC, ) ) Plaintiff, ) ) v. ) Case No. 4:18CV2039 HEA ) KIMERA LABS, INC., ) ) Defendant, )

OPINION, MEMORANDUM AND ORDER

This matter is before the Court on Defendant Kimera Labs, Inc.’s Motion for Partial Summary Judgment, [Doc. No. 215]. Plaintiff opposes the Motion. The Motion will be denied. Kimera (hereinafter “Defendant”) seeks summary judgment on its Fourth Counterclaim for trademark infringement, in violation of 15 U.S.C. § 1114(1); Fifth Counterclaim for false designation of origin/unfair competition in violation of 15 U.S.C. § 1125(2); Sixth Counterclaim for False Advertising in violation of 15 U.S.C. 1125; and Seventh Counterclaim for Comparative False Advertising in violation of 15 U.S.C. § 1125. Defendant argues the uncontroverted material facts establish a likelihood of confusion between its regenerative medicine exosome product sold under the XOGLO trademark with Plaintiff’s products sold under the mark XoFlo and ExoFlo. Defendant also seeks summary judgment on its claim that Plaintiff made false and/or misleading statements of fact in advertising its products by making

false statements about test results comparing the properties of the products at issue. Plaintiff responds through its argument that these issues cannot be resolved through a summary judgment motion because they involve fact intensive inquiries

of disputed material facts. Legal Standard Summary judgment is appropriate when there are no genuine issues of material fact, and the moving party can demonstrate that it is entitled to judgment

as a matter of law. Fed. R. Civ. P. 56(a); Paulino v. Chartis Claims, Inc., 774 F.3d 1161, 1163 (8th Cir. 2014). “A dispute is genuine if the evidence is such that it could cause a reasonable jury to return a verdict for either party; a fact is material

if its resolution affects the outcome of the case.” Amini v. City of Minneapolis, 643 F.3d 1068, 1074 (8th Cir. 2011) (citing Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986)). To preclude the entry of summary judgment, the non-moving party must

make a sufficient showing on every essential element of its case for which it has the burden of proof at trial. Celotex Corp. v. Catrett, 477 U.S. 317, 322–23 (1986). The evidence is viewed “in the light most favorable to the nonmoving party,”

which includes drawing all reasonable inferences in that party's favor. Pedersen v. Bio-Med. Applications of Minn., 775 F.3d 1049, 1053 (8th Cir. 2015) (quoting Johnson v. Wells Fargo Bank, N.A., 744 F.3d 539, 541 (8th Cir. 2014)). But

“[c]redibility determinations, the weighing of the evidence, and the drawing of legitimate inferences from the facts are jury functions, not those of a judge.” Liberty Lobby, 477 U.S. at 255, 106 S.Ct. 2505. A fact is material if it might affect

the outcome of the lawsuit. Id. “To defeat a motion for summary judgment, a party may not rest upon allegations, but must produce probative evidence sufficient to demonstrate a genuine issue [of material fact] for trial.” Davenport v. Univ. of Ark. Bd. of Trs., 553 F.3d 1110, 1113 (8th Cir. 2009).

Discussion Trademark Infringement and False Designation of Origin and Unfair Competition

The relevant portions of the Lanham Act provide: 1) Any person who shall, without the consent of the registrant—

(a) use in commerce any reproduction, counterfeit, copy, or colorable imitation of a registered mark in connection with the sale, offering for sale, distribution, or advertising of any goods or services on or in connection with which such use is likely to cause confusion, or to cause mistake, or to deceive; or

(b) reproduce, counterfeit, copy, or colorably imitate a registered mark and apply such reproduction, counterfeit, copy, or colorable imitation to labels, signs, prints, packages, wrappers, receptacles or advertisements intended to be used in commerce upon or in connection with the sale, offering for sale, distribution, or advertising of goods or services on or in connection with which such use is likely to cause confusion, or to cause mistake, or to deceive, shall be liable in a civil action by the registrant for the remedies hereinafter provided. Under subsection (b) hereof, the registrant shall not be entitled to recover profits or damages unless the acts have been committed with knowledge that such imitation is intended to be used to cause confusion, or to cause mistake, or to deceive.

As used in this paragraph, the term “any person” includes the United States, all agencies and instrumentalities thereof, and all individuals, firms, corporations, or other persons acting for the United States and with the authorization and consent of the United States, and any State, any instrumentality of a State, and any officer or employee of a State or instrumentality of a State acting in his or her official capacity. The United States, all agencies and instrumentalities thereof, and all individuals, firms, corporations, other persons acting for the United States and with the authorization and consent of the United States, and any State, and any such instrumentality, officer, or employee, shall be subject to the provisions of this chapter in the same manner and to the same extent as any nongovernmental entity.

15 U.S.C.A. § 1114.

(a) Civil action

(1) Any person who, on or in connection with any goods or services, or any container for goods, uses in commerce any word, term, name, symbol, or device, or any combination thereof, or any false designation of origin, false or misleading description of fact, or false or misleading representation of fact, which—

(A) is likely to cause confusion, or to cause mistake, or to deceive as to the affiliation, connection, or association of such person with another person, or as to the origin, sponsorship, or approval of his or her goods, services, or commercial activities by another person, or

(B) in commercial advertising or promotion, misrepresents the nature, characteristics, qualities, or geographical origin of his or her or another person’s goods, services, or commercial activities, shall be liable in a civil action by any person who believes that he or she is or is likely to be damaged by such act.

15 U.S.C. §1125(a)(1).

To determine whether a likelihood of confusion exists, courts typically apply a balancing test with six factors.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Direct Biologics v. Kimera Labs, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/direct-biologics-v-kimera-labs-inc-moed-2024.